01 Growing Demand for Plasma-Derived Therapies Drives Fractionation Capacity Expansion The plasma fractionation market is expanding as healthcare systems face sustained demand for plasma-derived medicines used to treat immunodeficiencies, bleeding disorders, and other rare and chronic conditions. Immunoglobulins remain an important area of demand, encouraging manufacturers to improve plasma processing efficiency and expand fractionation infrastructure. Companies are also investing in new production facilities and technologies to make better use of donated plasma and strengthen the long-term supply of essential therapies. CSL has highlighted opportunities to improve immunoglobulin and albumin yields through better plasma allocation, data analytics, and operational improvements. For instance, in July 2025, Grifols announced plans for a new plasma fractionation facility in Lliçà de Vall, Spain, aimed at strengthening its European manufacturing network and responding to growing demand for plasma-derived medicines. The facility is being developed as part of a highly digitalised biotechnology hub and is designed to support more efficient and sustainable plasma processing.
02 Regional Plasma Self-Sufficiency Strengthens Global Supply Chains The plasma fractionation market is increasingly moving toward regional supply models as governments and manufacturers seek greater control over the availability of plasma-derived medicines. Countries are developing local plasma collection networks, fractionation facilities, testing infrastructure, and integrated supply chains to reduce dependence on imported plasma products. This trend is particularly visible in emerging markets, where building domestic plasma capabilities can improve the reliability of treatment supplies and strengthen healthcare resilience. For instance, in June 2026, Grifols expanded its plasma-derived medicines program in Egypt through a new growth plan focused on expanding plasma collection and industrial capacity. The initiative is developing an integrated plasma ecosystem that brings together donation centres, plasma testing, logistics, and fractionation capabilities, supporting Egypt's goal of greater self-sufficiency in plasma-derived medicines.
01 Rising Demand for Plasma-Derived Medicines The plasma fractionation market is being driven by increasing demand for plasma-derived medicinal products, particularly immunoglobulins, albumin, and coagulation factors. These therapies are used to manage immunodeficiency disorders, bleeding conditions, and other serious diseases, making a reliable supply of fractionated plasma increasingly important. The World Health Organization emphasizes that governments need sustainable plasma and blood programs to ensure adequate supplies of immunoglobulins and coagulation factors. This is strengthening plasma fractionation market demand and influencing plasma fractionation market trends toward greater collection and processing capacity.
01 Limited Availability of Plasma Donations and Supply Chain Dependence The market faces restraints because plasma collection depends on a sufficient and consistent donor base. Collection capacity can vary considerably between countries, while some regions remain highly dependent on imported plasma-derived medicines. The WHO reports that only a limited number of countries fractionate domestically collected plasma, with many countries relying on imports for plasma-derived medicinal products. These limitations create plasma fractionation industry challenges and can restrict the ability of manufacturers to respond quickly to increasing therapeutic requirements.
01 Expansion of Domestic Plasma Collection and Fractionation Capacity The market presents significant opportunities through the expansion of domestic plasma collection programs and local fractionation infrastructure. Governments are increasingly looking to strengthen self-sufficiency in plasma-derived medicines and reduce dependence on international supply chains. Investment in donor centres, fractionation facilities, purification technologies, and integrated manufacturing networks can create new plasma fractionation market opportunities while supporting long-term plasma fractionation market growth. The WHO has also highlighted policy approaches that allow countries to use domestic plasma through contract or toll fractionation arrangements.
01 Maintaining Supply Resilience While Expanding Plasma Processing The plasma fractionation market continues to face the challenge of maintaining a reliable supply of plasma while expanding processing capacity and meeting stringent quality and safety requirements. Fractionation involves multiple stages of plasma collection, testing, pooling, separation, purification, and manufacturing, making the supply chain highly dependent on consistent donor availability and efficient processing. Shortages of immunoglobulins in several European markets have demonstrated how disruptions or unexpected increases in demand can place pressure on the supply of plasma-derived medicines. These conditions are shaping the plasma fractionation market outlook and encouraging investment in more resilient collection and manufacturing systems.
February 2026 Octapharma strengthened its plasma fractionation operations by expanding production capacity for immunoglobulin and coagulation factor therapies. The investment enhances global access to plasma-derived medicinal products.
October 2025 Takeda expanded its plasma-derived therapies business through investments in manufacturing infrastructure and plasma collection networks. The initiative supports growing demand for rare disease and immunology treatments.
August 2025 Grifols expanded manufacturing operations with new plasma fractionation capabilities designed to increase production efficiency and improve global product availability. The expansion strengthens supply chain resilience.
May 2025 CSL Behring expanded plasma collection capacity by opening new donation centers to strengthen the global supply of plasma-derived therapies. The investment supports increasing demand for immunoglobulins, albumin, and coagulation factors.